| Latest Glaxosmithkline News Headlines |
| Date | Time | Source | |
| 11/20/2008 | 5:43PM | PRNUS | FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood
PHILADELPHIA, Nov. 20 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE:GSK) today announced that the United States Food and Drug Administration (FDA) granted accelerated approval for PROMACTA(R) (eltrombopag) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP... More...>> |
| 11/20/2008 | 9:20AM | PRNUS | Beacon Equity Issues Technical Trade Alerts on Drug Manufacturers: NVS, JNJ, PFE, GSK, ABT, AZN
DALLAS, Nov. 20 /PRNewswire/ -- BeaconEquity.com announces the availability of Trade Alerts on stocks making news today.
Investors can view all of the daily trading notes for free by visiting: http://www.beaconequity.com/m
Today's Trade Alerts include: Novartis AG (NYSE:NVS), Johnson & Johnson (NYSE:JNJ), Pfizer Inc... More...>> |
| 11/02/2008 | 7:54PM | PRNUS | New Data Reveal People with Chronic Diseases are Unaware of Their Health Status
Knowing Your Risk for Chronic Diseases is a Critical First Step to Better Health
PHILADELPHIA, Nov. 2 /PRNewswire/ -- Nearly half of all Americans suffer from one or more chronic diseases, many of which are manageable and preventable. Data released today show that many people, despite knowing that they have a chronic... More...>> |
| 10/29/2008 | 8:44PM | PRNUS | GlaxoSmithKline to Acquire Genelabs Technologies to Increase Focus on Novel Small Molecule Therapies for Hepatitis C
PHILADELPHIA, Oct. 29 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE:GSK) (LSE:GSK) and Genelabs Technologies, Inc. (NASDAQ:GNLB) announced today that they have entered into a definitive agreement pursuant to which GSK will acquire Genelabs for approximately $57 million (pounds Sterling 35 million) through a tender... More...>> |
| 10/21/2008 | 10:11AM | PRNUS | GlaxoSmithKline to Acquire the Leading Dry Mouth Brand, Biotene
- Move strengthens therapeutic oral healthcare portfolio -
LONDON, Oct. 21 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE:GSK) Consumer Healthcare announced today that it has reached an agreement with Laclede, a privately held company, to purchase the leading Dry Mouth brand Biotene(R) for $170 million. The transaction... More...>> |
| 10/20/2008 | 10:11AM | PRNUS | GSK Notice of Third Quarter 2008 Results Announcement and Teleconference
PHILADELPHIA, Oct. 20 /PRNewswire-FirstCall/ -- On Wednesday, October 22, 2008, GlaxoSmithKline plc (NYSE:GSK) will announce its third quarter financial results for the three months ended September 30, 2008. The announcement is scheduled for release to the London Stock Exchange at approximately 12:00pm UK, 7:00 am... More...>> |
| 10/17/2008 | 10:25AM | PRNUS | Seven Summits Research Releases Comments on GOOG, MOS, JNPR, GSK, and LEG
CHICAGO, Oct. 17 /PRNewswire/ -- Seven Summits Research releases NewsBites on key stocks.
Seven Summits Strategic Investments NewsBites are available to all investors at:
http://www.go7now.com/nb/1017Y (Note: You may have to copy this link into your browser then press the [ENTER] key.)
Today's Seven Summits Strategic... More...>> |
| 09/23/2008 | 9:52AM | PRNUS | GlaxoSmithKline Named a 2008 100 Best Company by Working Mother Magazine
- Focus on Healthy High Performance Wins Praise for Supporting Healthy, Balanced Lives
PHILADELPHIA, Sept. 23 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE:GSK) today announced that it was named one of the 2008 Working Mother 100 Best Companies by Working Mother magazine. From flextime and telecommuting to creating... More...>> |
| 09/16/2008 | 8:00AM | PRNUS | GSK and XenoPort Announce Submission of New Drug Application Requesting FDA Approval of Solzira(TM) for Restless Legs Syndrome
Submission Based on Results from Pivotal Trials Evaluating Efficacy, Safety and Maintenance of Effect in Patients with Moderate-to-Severe Primary RLS
RESEARCH TRIANGLE PARK, N.C. and SANTA CLARA, Calif., Sept. 16
/PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE:GSK) and XenoPort, Inc. (NASDAQ:XNPT) announced today that... More...>> |
| 09/09/2008 | 11:47AM | PRNUS | Ellen Strahlman Appointed Chief Medical Officer at GlaxoSmithKline
PHILADELPHIA, Sept. 9 /PRNewswire-FirstCall/ -- Ellen Strahlman, M.D., M.H.Sc., has been appointed Chief Medical Officer (CMO) at GlaxoSmithKline (NYSE:GSK).
Ellen joins GSK from Pfizer Inc. where she was Vice President, Licensing, Worldwide Business Development. During her career, Ellen has worked in a variety of... More...>> |
| 09/03/2008 | 8:07AM | PRNUS | GlaxoSmithKline Offers New Purchasing Options to Help Employers Overcome Barriers to Pandemic Stockpiling of Relenza(R)
PHILADELPHIA, Sept. 3 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE:GSK) announced today the launch of the RELENZA(R) (zanamivir) Inhalation Powder Pandemic Readiness for Employers Program (P.R.E.P.) that enables businesses two options when stockpiling RELENZA in preparation for an influenza pandemic. Under the new... More...>> |
| 08/21/2008 | 9:00AM | PRNUS | GlaxoSmithKline To Post Quarterly US Grants Report
PHILADELPHIA, Aug. 21 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE:GSK) today announced that, beginning in February 2009, the company will proactively report educational and charitable grants provided to US health-related organizations. The report will be updated on a quarterly basis and will include grants provided... More...>> |
| 08/19/2008 | 9:00AM | PRNUS | New Study Suggests Increasing Prescription Co-payments for Chronic Diseases May Worsen Health Disparities, Adversely Affect Heal
Patients in Low-Income Geographic Areas Are More Sensitive to Cost-Sharing Increases
PHILADELPHIA, Aug. 19 /PRNewswire-FirstCall/ -- The relationship between medication adherence and income level may contribute to the disparities in health observed across socioeconomic groups, according to a recent study published in... More...>> |
| 08/11/2008 | 2:27PM | PRNUS | GSK Begins Shipments of Fluarix(R) and FluLaval(R) to U.S. Customers for 2008-2009 Influenza Season
GSK anticipates delivery of at least half of shipments by the end of August
PHILADELPHIA, Aug. 11 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE:GSK) today announced that it will begin shipment of FLULAVAL(R) [Influenza Virus Vaccine] and FLUARIX(R) [Influenza Virus Vaccine] to U.S. customers for the 2008-2009 influenza... More...>> |
| 08/07/2008 | 2:30PM | PRNUS | Analysis of Six Clinical Trials Finds EPZICOM(R) Effective in Treatment-Naive HIV Patients With Both High and Low Baseline Viral
MEXICO CITY, Aug. 7 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE:GSK) announced that a retrospective analysis of six clinical trials found that anti-HIV regimens containing EPZICOM (abacavir + lamivudine) were effective in treatment-naive patients regardless of baseline viral loads. One of the trials analyzed was... More...>> |
| 08/07/2008 | 1:30PM | PRNUS | Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV Treatment-Naive P
MEXICO CITY, Aug. 7 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE:GSK) today announced that 96-week data from the HEAT study show that once-daily EPZICOM (abacavir + lamivudine) provides comparable efficacy to once-daily Truvada(R) (tenofovir DF + emtricitabine) as a first-line option for the treatment of HIV. The... More...>> |
| 08/06/2008 | 1:05PM | PRNUS | Pooled-Analysis of 54 Clinical Studies Shows No Increased Risk of Heart Attack With Abacavir Therapy
MEXICO CITY, Aug. 6 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE:GSK) (GSK) announced today that a review of data from over 14,600 patients in 54 clinical studies showed no increased risk of myocardial infarction associated with the anti-HIV medication abacavir. GSK conducted this review upon learning that the analysis... More...>> |
| 07/16/2008 | 12:43PM | PRNUS | GlaxoSmithKline plc Q2 Results Announcement, Webcast and Telephone Link - Wednesday, July 23, 2008
PHILADELPHIA, July 16 /PRNewswire-FirstCall/ -- On Wednesday, July 23rd, GlaxoSmithKline plc (NYSE:GSK) will announce its second quarter financial results for the three months ended June 30, 2008. The press release is scheduled for distribution at approximately 7:00 am EDT and will be available on the website, http://www.gsk.com/... More...>> |
| 06/30/2008 | 9:03AM | PRNUS | GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval
LONDON and PHILADELPHIA, June 30 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE:GSK) today provided the following update regarding its application to the U.S. Food and Drug Administration (FDA) for approval of CERVARIX(R), its vaccine to prevent cervical cancer.
GSK has submitted its response to questions raised by... More...>> |
| 06/27/2008 | 11:15AM | PRNUS | Data Show Significantly More Patients Were Pain-Free with Treximet(TM) (sumatriptan and naproxen sodium) Tablets in the Acute Tr
Treximet was superior to placebo in producing pain-freedom at two hours and sustained pain-freedom from two through 24 hours
BOSTON, June 27 /PRNewswire-FirstCall/ -- Patients suffering from probable migraine, which is defined as a sub-type of migraine that meets all but one of the migraine diagnostic criteria, frequently... More...>> |